References
[1] Wolf G, Chen S, Ziyadeh FN (2005) From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. DIABETES 54: 1626-1634
[2] Hartleben B, Godel M, Meyer-Schwesinger C, et al. (2010) Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J CLIN INVEST 120: 1084-1096
[3] Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y (2004) Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J AM SOC NEPHROL 15: 2637-2647
[4] Li H, Jiang T, Lin Y, Zhao Z, Zhang N (2006) HGF protects rat mesangial cells from high-glucose-mediated oxidative stress. AM J NEPHROL 26: 519-530
[5] Flaquer M, Franquesa M, Vidal A, et al. (2012) Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes. DIABETOLOGIA 55: 2059-2068
[6] Xu W, Ge Y, Liu Z, Gong R (2015) Glycogen synthase kinase 3beta orchestrates microtubule remodeling in compensatory glomerular adaptation to podocyte depletion. J BIOL CHEM 290: 1348-1363
[7] Bao H, Ge Y, Peng A, Gong R (2015) Fine-tuning of NFkappaB by glycogen synthase kinase 3beta directs the fate of glomerular podocytes upon injury. KIDNEY INT 87: 1176-1190
[8] Paeng J, Chang JH, Lee SH, et al. (2014) Enhanced glycogen synthase kinase-3beta activity mediates podocyte apoptosis under diabetic conditions. APOPTOSIS 19: 1678-1690
[9] Zhou S, Wang P, Qiao Y, et al. (2016) Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3beta Reinforces the Nrf2 Antioxidant Defense against Podocytopathy. J AM SOC NEPHROL 27: 2289-2308
[10] Li C, Ge Y, Dworkin L, Peng A, Gong R (2016) The beta isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy. J PATHOL 239: 23-35
[11] Zhang C, Hou B, Yu S, Chen Q, Zhang N, Li H (2016) HGF alleviates high glucose-induced injury in podocytes by GSK3beta inhibition and autophagy restoration. Biochim Biophys Acta 1863: 2690-2699
[12] Kenichiro K, Hitonari N, Yuki K, et al. (2011) Defective glycosylation of a-dystroglycan contributes to podocyte flattening. KIDNEY INT 79: 311-316
[13] Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. (2008) Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product-Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C- -Dependent Pathway. DIABETES 57: 460-469
[14] Wu L, Feng Z, Cui S, et al. (2013) Rapamycin upregulates autophagy by inhibiting the mTOR-ULK1 pathway, resulting in reduced podocyte injury. PLOS ONE 8: e63799
[15] Shankland SJ, Pippin JW, Reiser J, Mundel P (2007) Podocytes in culture: past, present, and future. KIDNEY INT 72: 26-36
[16] Tagawa A, Yasuda M, Kume S, et al. (2016) Impaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy. DIABETES 65: 755-767
[17] Beurel E, Grieco SF, Jope RS (2015) Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 148: 114-131
[18] Ren F, Zhang L, Zhang X, et al. (2016) Inhibition of glycogen synthase kinase 3beta promotes autophagy to protect mice from acute liver failure mediated by peroxisome proliferator-activated receptor alpha. CELL DEATH DIS 7: e2151
[19] Azoulay-Alfaguter I, Elya R, Avrahami L, Katz A, Eldar-Finkelman H (2015) Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. ONCOGENE 34: 4613-4623
[20] Marchand B, Arsenault D, Raymond-Fleury A, Boisvert FM, Boucher MJ (2015) Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells. J BIOL CHEM 290: 5592-5605
[21] Settembre C, Di Malta C, Polito VA, et al. (2011) TFEB links autophagy to lysosomal biogenesis. SCIENCE 332: 1429-1433
[22] Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H (2013) Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J BIOL CHEM 288: 1295-1306
[23] Marchand B, Arsenault D, Raymond-Fleury A, Boisvert FM, Boucher MJ (2015) Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells. J BIOL CHEM 290: 5592-5605
[24] Peng KY, Horng LY, Sung HC, Huang HC, Wu RT (2011) Hepatocyte growth factor has a role in the amelioration of diabetic vascular complications via autophagic clearance of advanced glycation end products: Dispo85E, an HGF inducer, as a potential botanical drug. METABOLISM 60: 888-892
[25] Liang X, Wang P, Chen B, et al. (2020) Glycogen synthase kinase 3b hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease. Kidney Int 97: 175-192
[26] de Munck E, Palomo V, Muñoz-Sáez E, et al. (2016) Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. PLOS ONE 11: e162723
[27] Shimada K, Motoi Y, Ishiguro K, et al. (2012) Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. NEUROBIOL DIS 46: 101-108
[28] Wei H, Qu H, Wang H, et al. (2017) Corrigendum to "1, 25-Dihydroxyvitamin-D3 prevents the development of diabetic cardiomyopathy in type 1 diabetic rats by enhancing autophagy via inhibiting the beta-catenin/TCF4/GSK-3beta/mTOR pathway" [J. Steroid. Biochem. Mol. Biol. 168 (2017) 71-90]. J Steroid Biochem Mol Biol 174: 312-313
[29] Parr C, Carzaniga R, Gentleman SM, Van Leuven F, Walter J, Sastre M (2012) Glycogen Synthase Kinase 3 Inhibition Promotes Lysosomal Biogenesis and Autophagic Degradation of the Amyloid-Precursor Protein. MOL CELL BIOL 32: 4410-4418
[30] Li L, Friedrichsen HJ, Andrews S, et al. (2018) A TFEB nuclear export signal integrates amino acid supply and glucose availability. NAT COMMUN 9: 2685
[31] Zhao X, Chen Y, Tan X, et al. (2018) Advanced glycation end-products suppress autophagic flux in podocytes by activating mammalian target of rapamycin and inhibiting nuclear translocation of transcription factor EB. The Journal of Pathology
[32] Settembre C, De Cegli R, Mansueto G, et al. (2013) TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. NAT CELL BIOL 15: 647-658
[33] Pastore N, Blomenkamp K, Annunziata F, et al. (2013) Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha-1-anti-trypsin deficiency. EMBO MOL MED 5: 397-412
[34] Rega LR, Polishchuk E, Montefusco S, et al. (2016) Activation of the transcription factor EB rescues lysosomal abnormalities in cystinotic kidney cells. KIDNEY INT 89: 862-873